Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184286 | 0.74 | INMT (0.38) | HTR2CADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL24326976 | 0.70 | HTR2C (0.38) | HTR2CNOTUM | |
| SCHEMBL256749 | 0.70 | NOTUM (0.56) | HTR2CNOTUM | |
| SCHEMBL2625804 | 0.70 | ALOX12 (0.50) | HTR2CNOTUMADRA2ACYP2D6ADRA2B | |
| SCHEMBL12950956 | 0.70 | HTR2C (0.39) | HTR2CNOTUMALOX12 | |
| SCHEMBL6975536 | 0.69 | HAAO (0.38) | NOTUM | |
| SCHEMBL11784424 | 0.67 | KMT2A (0.34) | HTR2CADRA1DADRA1AADRA1BINMT | |
| SCHEMBL256752 | 0.67 | HTR2A (0.47) | HTR2C | |
| SCHEMBL19121514 | 0.67 | INMT (0.41) | HTR2CADRA1DADRA1AADRA1BINMT | |
| SCHEMBL2625783 | 0.67 | NOTUM (0.40) | HTR2CNOTUMADRA2ACYP2D6ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | HTR2C 1865/4885NOTUM 4384/4885ADRA2A 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.